Akorn shareholders approve merger with Fresenius Kabi

LAKE FOREST - Akorn Inc. shareholders have overwhelmingly voted to approve the company's acquisition by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.

The transaction remains subject to regulatory approvals and customary closing conditions, and the companies expect the acquisition will close by early 2018.

Fresenius Kabi announced in April it would acquisition of Lake Forest-based generic drugmaker for $4.3 billion. Fresenius will get a stronger foothold in the U.S., with access to a network of retail pharmacies and outpatient clinics as well as the hospitals where it has traditionally marketed its products.